Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Ultrahigh-Field MRI May Detect Additional Pathology in EAE
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.
Health Care Resource Use and Cost Of Multiple Sclerosis in Slovakia: Results from the National Cross-Sectional Study.
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Papers: 31 Jul 2015 - 7 Aug 2015
Papers: 8 May 2015 - 15 May 2015
Papers: 22 Dec 2015 - 29 Dec 2015
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Resisting Arrest
Episode 80 with Dr. Kaarina Kowalec on adverse MS drug reactions
Papers: 17 Jul 2015 - 24 Jul 2015
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
European Multiple Sclerosis Platform 2016 Spring Conference
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Papers: 11 Sep 2015 - 18 Sep 2015
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.
Cortical functional modifications following optic neuritis.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Histamine and Immune Biomarkers in CNS Disorders.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.
Does Current Portuguese Financing Model for Multiple Sclerosis Covers for Estimated Needs?
Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies.

Pages